An Alzheimer’s Disease-Derived Biomarker Signature Identifies Parkinson’s Disease Patients with Dementia
Tóm tắt
Từ khóa
Tài liệu tham khảo
RE Tanzi, 2005, Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective, Cell, 120, 545, 10.1016/j.cell.2005.02.008
A Wright Willis, 2010, Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries, Neuroepidemiology, 34, 143, 10.1159/000275491
JM Fearnley, 1991, Ageing and Parkinson's disease: substantia nigra regional selectivity, Brain, 114, 2283, 10.1093/brain/114.5.2283
CH Williams-Gray, 2007, Evolution of cognitive dysfunction in an incident Parkinson's disease cohort, Brain, 130, 1787, 10.1093/brain/awm111
Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. 2008;23: 837–844.
TC Buter, 2008, Dementia and survival in Parkinson disease: a 12-year population study, Neurology, 70, 1017, 10.1212/01.wnl.0000306632.43729.24
R Mayeux, 1992, A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender, Arch Neurol, 49, 492, 10.1001/archneur.1992.00530290076015
Rosenthal E, Brennan L, Xie S, Hurtig H, Milber J, Weintraub D, et al. Association between cognition and function in patients with Parkinson disease with and without dementia. 2010;25: 1170–1176.
JC Pressley, 2003, The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism, Neurology, 60, 87, 10.1212/WNL.60.1.87
K Marek, 2011, The parkinson progression marker initiative (PPMI), Prog Neurobiol, 95, 629, 10.1016/j.pneurobio.2011.09.005
K Marek, 2008, Biomarkers for Parkison's disease: tools to assess Parkinson's disease onset and progression, Ann Neurol, 64, S111, 10.1002/ana.21602
TB Sherer, 2011, Biomarkers for Parkinson's disease, Sci Transl Med, 3, 79ps14, 10.1126/scitranslmed.3002488
Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, et al. Cerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias. 2011;26: 1428–1435.
K Marder, 1995, The frequency and associated risk factors for dementia in patients with Parkinson's disease, Arch Neurol, 52, 695, 10.1001/archneur.1995.00540310069018
EY Uc, 2009, Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort, Neurology, 73, 1469, 10.1212/WNL.0b013e3181bf992f
TA Hughes, 2000, A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease, Neurology, 54, 1596, 10.1212/WNL.54.8.1596
D Aarsland, 2001, Risk of dementia in Parkinson's disease: a community-based, prospective study, Neurology, 56, 730, 10.1212/WNL.56.6.730
Morley JF, Xie SX, Hurtig HI, Stern MB, Colcher A, Horn S, et al. Genetic influences on cognitive decline in Parkinson's disease. 2012;27: 512–518.
CH Williams-Gray, 2009, The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort, Brain, 132, 2958, 10.1093/brain/awp245
J Neumann, 2009, Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease, Brain, 132, 1783, 10.1093/brain/awp044
A Siderowf, 2010, CSF amyloid {beta} 1–42 predicts cognitive decline in Parkinson disease, Neurology, 75, 1055, 10.1212/WNL.0b013e3181f39a78
LM Shaw, 2009, Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects, Ann Neurol, 65, 403, 10.1002/ana.21610
MT Pellecchia, 2013, Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson’s disease patients, J Neurol, 260, 438, 10.1007/s00415-012-6648-6
AS Chen‐Plotkin, 2011, Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease, Ann Neurol, 69, 655, 10.1002/ana.22271
Mollenhauer B, Rochester L, Chen‐Plotkin A, Brooks D. What can biomarkers tell us about cognition in Parkinson's disease?. 2014;29: 622–633.
C Davatzikos, 2009, Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index, Brain, 132, 2026, 10.1093/brain/awp091
D Weintraub, 2012, Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease, Brain, 135, 170, 10.1093/brain/awr277
AS Chen-Plotkin, 2014, Unbiased Approaches to Biomarker Discovery in Neurodegenerative Diseases, Neuron, 84, 594, 10.1016/j.neuron.2014.10.031
P Mattila, 2000, Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease, Acta Neuropathol, 100, 285, 10.1007/s004019900168
AJ Hughes, 1993, A clinicopathologic study of 100 cases of Parkinson's disease, Arch Neurol, 50, 140, 10.1001/archneur.1993.00540020018011
MN Sabbagh, 2009, Parkinson disease with dementia: comparing patients with and without Alzheimer pathology, Alzheimer Dis Assoc Disord, 23, 295, 10.1097/WAD.0b013e31819c5ef4
DJ Irwin, 2012, Neuropathologic substrates of Parkinson disease dementia, Ann Neurol, 72, 587, 10.1002/ana.23659
KA Jellinger, 2008, Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease, Acta Neuropathol, 115, 427, 10.1007/s00401-008-0347-5
WR Gibb, 1988, The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease, J Neurol Neurosurg Psychiatry, 51, 745, 10.1136/jnnp.51.6.745
MW Weiner, 2015, 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception, Alzheimers Dement, 11, e1, 10.1016/j.jalz.2014.11.001
Mollenhauer B, Rochester L, Chen‐Plotkin A, Brooks D. What can biomarkers tell us about cognition in Parkinson's disease?. 2014;29: 622–633.
Lucas JA, Ivnik RJ, Smith GE, Bohac DL, Tangalos EG, Kokmen E, et al. Normative data for the Mattis dementia rating scale. 1998;20: 536–547.
Weintraub D, Oehlberg KA, Katz IR, Stern MB. Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. 2006;14: 169–175.
Fahn S, Elton R. Unified rating scale for Parkinson’s disease. 1987: 153–163.
AM Shapiro, 1999, Construct and concurrent validity of the Hopkins Verbal Learning Test-revised, Clin Neuropsychol, 13, 348, 10.1076/clin.13.3.348.1749
J BR Brandt, 2001, The Hopkins Verbal Learning Test-Revised, Psychological Assessment Resources
D Weintraub, 2004, Evidence for impaired encoding and retrieval memory profiles in Parkinson disease, Cogn Behav Neurol, 17, 195
Chahine LM, Qiang J, Ashbridge E, Minger J, Yearout D, Horn S, et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. 2013;70: 852–858.
Hoehn M. Yahr. 1967: V7.
J Jankovic, 1990, Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group, Neurology, 40, 1529, 10.1212/WNL.40.10.1529
D Tsuang, 2012, GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology, Neurology, 79, 1944, 10.1212/WNL.0b013e3182735e9a
A Olsson, 2005, Simultaneous measurement of beta-amyloid(1–42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology, Clin Chem, 51, 336, 10.1373/clinchem.2004.039347
Su Y, Yajima M, Gelman AE, Hill J. Multiple imputation with diagnostics (mi) in R: Opening windows into the black box. 2011;45: 1–31.
Irwin DJ, Lee VM, Trojanowski JQ. Parkinson's disease dementia: convergence of [alpha]-synuclein, tau and amyloid-[beta] pathologies. 2013;14: 626–636.
B Mollenhauer, 2006, Beta-amlyoid 1–42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia, Dement Geriatr Cogn Disord, 22, 200, 10.1159/000094871
H Braak, 2003, Staging of brain pathology related to sporadic Parkinson’s disease, Neurobiol Aging, 24, 197, 10.1016/S0197-4580(02)00065-9
H Braak, 2006, Anonymous Parkinson’s Disease and Related Disorders, 89
ME Kalaitzakis, 2008, Striatal beta-amyloid deposition in Parkinson disease with dementia, J Neuropathol Exp Neurol, 67, 155, 10.1097/NEN.0b013e31816362aa
Y Compta, 2011, Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?, Brain, 134, 1493, 10.1093/brain/awr031
KA Jellinger, 2008, A critical reappraisal of current staging of Lewy-related pathology in human brain, Acta Neuropathol, 116, 1, 10.1007/s00401-008-0406-y
K Jellinger, 2002, Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease, J Neural Transm, 109, 329, 10.1007/s007020200027
JH Kramer, 1989, Differentiation of Alzheimer's, Huntington's, and Parkinson's disease patients on the basis of verbal learning characteristics, Neuropsychology, 3, 111, 10.1037/h0091766
B Pillon, 1993, Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases, Arch Neurol, 50, 374, 10.1001/archneur.1993.00540040036010
LK Clinton, 2010, Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline, J Neurosci, 30, 7281, 10.1523/JNEUROSCI.0490-10.2010
JE Duda, 2002, Concurrence of α-synuclein and tau brain pathology in the Contursi kindred, Acta Neuropathol, 104, 7, 10.1007/s00401-002-0563-3
VM Lee, 2004, More than just two peas in a pod: common amyloidogenic properties of tau and α-synuclein in neurodegenerative diseases, Trends Neurosci, 27, 129, 10.1016/j.tins.2004.01.007
BI Giasson, 2003, Initiation and synergistic fibrillization of tau and alpha-synuclein, Science, 300, 636, 10.1126/science.1082324
RS Doody, 2014, Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease, N Engl J Med, 370, 311, 10.1056/NEJMoa1312889
S Salloway, 2014, Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease, N Engl J Med, 370, 322, 10.1056/NEJMoa1304839
AstraZeneca. An Efficacy and Safety Study of AZD3293 in Early Alzheimer's Disease (AMARANTH).
Eli Lilly and Company. Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4).
Eisai Inc. Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild Dementia Due to Alzheimer's Disease.